In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats
- 8 August 1995
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 50 (4), 545-556
- https://doi.org/10.1016/0006-2952(95)00159-w
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1Biochemical Pharmacology, 1995
- Pharmacokinetics of Antisense OligonucleotidesClinical Pharmacokinetics, 1995
- Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotidesBioorganic & Medicinal Chemistry Letters, 1994
- Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide againstrevfrom Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous InfusionAntisense Research and Development, 1994
- In VivoToxicological Effects ofrelA Antisense Phosphorothioates in CD-1 MiceAntisense Research and Development, 1994
- Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the MonkeyAntisense Research and Development, 1994
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993
- Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in MiceAntisense Research and Development, 1993
- Antisense oligonucleotides as antiviral agentsTrends in Biotechnology, 1992
- Characteristics of pharmacokinetic modelling in a phase I clinical trial of radiolabeled monoclonal antibodyControlled Clinical Trials, 1991